Please do not leave this page until complete. This can take a few moments.
The world is waiting for a Covid-19 vaccine or more evidence that other treatments can be effective against coronavirus. But recent setbacks in trials have made investors nervous.
That's why some drug stock experts say people shouldn't be betting on vaccine winners and losers.
Big Pharma giant (and Dow component) Johnson & Johnson recently announced it had to pause trials for its vaccine after a volunteer got sick. British multinational drug company AstraZeneca was forced to halt its trials last month as well and there are lingering questions from regulators.
And just this week, Eli Lilly, the maker of an antibody cocktail touted by President Trump after he was diagnosed with and treated for coronavirus, said it was pausing a clinical trial, too.
Shares of Eli Lilly and Regeneron, which makes another treatment that Trump received while he was hospitalized at Walter Reed, had surged following the President's endorsement.
Both companies have also filed for emergency-use approval for their treatments with the Food and Drug Administration.
Drugmakers and biotechs are understandably working feverishly to try to come up with a vaccine or treatment from Covid-19.
Pfizer, BioNTech, GlaxoSmithKline, Novavax and Moderna are some of the other leading companies working on a vaccine. All of them have received funding from the US government's Operation Warp Speed program as well.
But investors probably shouldn't rush into these stocks on hopes that one of them will be the first to come up with a successful vaccine.
For Big Phrama firms, a vaccine is unlikely to move the financial needle, so to speak.
"Larger companies like Pfizer and J&J are not looking to make a ton of money from a vaccine," said Kyle Dennis, founder of the BiotechBreakouts trading site.
Dennis noted that most of the vaccine makers will wind up having government-negotiated contracts. So a vaccine is probably not going to be a big revenue or profit generator.
Investors should also be wary of the Covid-19 vaccine and treatment stocks simply because many of them have already surged on hope and hype.
Regeneron is up more than 60% this year. Moderna and another small biotech named Inovio are each up about 300% in 2020.
And Novavax has skyrocketed a whopping 2,840% — from about $4 at the start of 2020 to a current price of $117.
"I'm skeptical of the so-called Covid plays. I'd personally avoid all of them. They're all overvalued. Even the companies that succeed could be overvalued," said Brad Loncar, a biotech investing expert who runs The Cancer Immunotherapy ETF and The China BioPharma ETF.
"There are a lot of people who aren't traditional biotech investors that are throwing money at headlines but not doing the homework to figure out the math of what any financial gains will be," Loncar added.
Loncar agreed with Dennis that few, if any, health care firms will generate significant long-term revenue or earnings from a vaccine or treatment.
He also said that a vaccine is ultimately more important than drugs that may alleviate Covid-19 symptoms.
"We have to have a vaccine. It's our ticket out of this. We're not going to fill football stadiums with 80,000 people until there is a vaccine," Loncar said.
But hopes of having at least one (if not more) vaccines ready in the next few months might be overly ambitious. Dennis noted that because biotechs and Big Pharma firms are moving so quickly to develop a coronavirus vaccine, there probably will be more setbacks in clinical trials.
"This is an aggressive schedule so that is a bit of a concern. Looking at these time tables, we've never produced a vaccine this quickly. So there are risks," Dennis said.
Investors need to focus more on other diseases, too, Loncar said.
For example, Loncar owns Moderna and BioNTech because of their pipeline of cancer drugs as opposed to coronavirus vaccines. He also owns shares of Gilead Sciences, whose remdesivir drug has also been used to treat Covid-19.
But Loncar noted that he's mainly bullish on Gilead because of its cancer drug portfolio. The company announced last month it was buying oncology biotech Immunomedics for $21 billion.
"The Gilead deal shows it is planning for post-Covid times," Loncar said.
Dennis also said investors should focus more on cancer and other severe illnesses than Covid. He recommends biotechs Black Diamond Therapeutics and Karyopharm Therapeutics. Dennis also likes Global Blood Therapeutics, which he told CNN Business he owns.
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments